Genentech Inks Licensing Deal With Kiniksa Pharmaceuticals
Genentech has inked a licensing and development deal with Bermuda-based biotech Kiniksa Pharmaceuticals for the company’s investigational drug vixarelimab.
The monoclonal antibody targets oncostatin M receptor beta. Genentech will focus its efforts on the drug candidate for treatment of fibrosis, given its potential for treating oncostatin M-mediated disease.
Kiniksa intends to complete its ongoing phase 2b clinical trial investigating the drug as a treatment for the skin disease prurigo nodularis.
Kiniksa will receive $100 million in upfront and near-term payments and is also eligible to receive up to approximately $600 million for achieving clinical, regulatory and sales-based milestones.
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s clinical-stage product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These pipeline assets are designed to modulate immunological pathways that are implicated across a spectrum of diseases. Based in Lexington, Massachusetts.
August 8, 2022